Matrix metalloproteinase-2 matrix metalloproteinase-9 and inducible nitric oxide synthase in oral leukoplakia: Immunohistochemistry and RT-PCR analysis

Journal of Biological Regulators and Homeostatic Agents

Volumn 22, Issue 2, 2008, Pages 125-130

  Tortorici, Silvia ^a   Mauro, A ^a   Burruano, F ^a   Difalco, P ^a   Leone, A ^a   Gerbino, A ^a   Buscemi, M ^a   Conti, P ^b   Mastrangelo, F ^b   Tete S ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

iNOS; MMP 2; MMP 9; Oral leukoplakia; RT PCR analysis

Indexed keywords

GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; ORAL BIOPSY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA, ORAL; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 48749132331     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Longterm treatment outcome of oral premalignant lesions. Oral Oncol 2006; 42:461-74.
2. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 2003; 14:47-62.
3. WHO Collaborating Centre for Oral Precancerous Lesions. Definitions of leukoplakia and related lesions: an aid to studies on oral precancers. Oral Surg 1978; 46:518-539.
4. Gale N, Pilch BZ, Sedransky D, El Nagzar A, Precursor Lesions. Barnes L, Eveson JW, Reichart P, Sedransky D, eds. World Health Organization Classification of Tumors pathology & genetic of Head Neck Tumors, Lyon 2005; p. 177-9.
5. Axéll T, Pindborg JJ, Smith CJ, van der Waal I. An International Collaborative Group on oral white lesions. Oral white lesions with special reference to precancerous and tabacco-related lesions: conclusions of an International Symposium held in Uppsala (Sweden, May 18-21 1994). J Oral Pathol Med 1996; 25:25-49.
6. Kingsley K, Johnson D, O'Malley S. Transfection of oral squamous cell carcinoma with human papillomavirus- 16 induces proliferative and morphological changes in vitro. Cancer Cell Int 2006; 6:14-18.
7. Pimenta FJ, Gomes DA, Perdigão PF, Barbosa AA, Romano-Silva MA, Gomez MV, Aldaz CH, De Marco L, Gomez RS. Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas. Int J Cancer 2006; 118: 1154-8.
8. Poate TWJ, Warnakulasuriya S. Effective management of smoking in an oral dysplasia clinic in London. Oral Diseases 2006; 12:22-26.
9. Al Madori G, Bussu F, Navarra P. Pilot phase IIA study for evaluation of the efficacy of folic acid in the treatment of laryngeal leucoplakia. Cancer 2006; 10:328-36.
10. Ghazali N, Bakri MM, Zain RB. Aggressive, multifocal oral verrucous leukoplakia: proliferative verrucous leukoplakia or not? J Oral Pathol Med 2003; 32:383-92.
11. Bagan JV, Jimenez Y, Sanchis JM, Poveda R, Milian MA, Murillo J, Scully C. Proliferative verrucous leukoplakia: high incidence of gingival squamous cell carcinoma. J Oral Pathol Med 2003; 32:379-82.
12. Ma N, Tagawa T, Hiraku Y, Murata M, Ding X, Kawanishi S. 8-Nitroguanine formation in oral leukoplakia, a premalignant lesion. Nitric Oxide 2006; 14:137-43.
13. Chaiyarit P, Ma N, Hiraku Y, Pinlaor S, Yongvanit P, Jintakanon D, Murata M, Oikawa S, Kawanishi S. Nitrative and oxidative DNA damage in oral lichen planus in relation to human oral carcinogenesis. Cancer Sci 2005; 96:553-9.
14. Cataldo DD, Gueders MM, Rocks N, Sounni NE, Evrard B, Bartsch P, Louis R, Noel A, Foidart JM. Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloprotease inhibitors. Cell Mol Biol 2003; 49:875-84.
15. Dahan M, Nawrocki B, Elkaïm R, Soell M, Bolcato-Bellemin AL, Birembaut P, Tenenbaum H. Expression of matrix metalloproteinases in healthy and diseased human gingiva. J Clin Periodontol 2001; 28:128-36.
16. Xue M, Le NT, Jackson CJ. Targetting matrix metalloproteases to improve cutaneous wound healing. Expert Opin Ther Targets 2006; 10:143-55.